This is a major derisking event for PHVS. The 83% attack rate reduction with statistical significance across all HAE types, combined with a clean safety profile, positions deucrictibant XR as a potential best-in-class oral prophylactic. Traders should watch for the NDA submission timeline (H1 2027) and potential partnership or M&A interest given the strength of the data across both on-demand and prophylactic formulations. The ongoing CREAATE study for AAE-C1INH provides additional upside optionality.
Price Chart
Executive Summary
Pharvaris announced overwhelmingly positive topline data from the CHAPTER-3 pivotal Phase 3 study of deucrictibant XR for prophylaxis of HAE attacks. The study met its primary endpoint with an 83% attack rate reduction versus placebo (p<0.0001) and all secondary endpoints were met with statistical significance, with a well-tolerated safety profile. This data supports planned NDA submissions starting in the first half of 2027, positioning deucrictibant as a potential first-in-class oral therapy with injectable-like efficacy for both on-demand and prophylactic treatment, which is a transformative event for this late-stage biotech company.
Key Facts
- Primary endpoint met: 83% attack rate reduction versus placebo (p<0.0001) in all three types of HAE.
- 87% attack rate reduction versus placebo observed in HAE Type 1 or Type 2 patients.
- All secondary efficacy endpoints met with statistical significance.
- Deucrictibant XR was well tolerated with no treatment-related serious adverse events.
- Marketing authorization applications planned starting in first half of 2027.
- Ongoing regulatory review of NDA for deucrictibant IR for on-demand treatment.
- Topline data from CREAATE study for AAE-C1INH anticipated in Q1 2027.
Financial Impact
Transformative pipeline event for a $2.6B market cap biotech; positive Phase 3 data in a large addressable market (HAE prophylaxis) with potential to capture significant market share from injectable therapies. No financial figures provided in the filing.
Risk Factors
- Regulatory risk: FDA review and potential approval uncertainties remain despite strong data.
- Commercial execution risk: Launching two products (IR and XR) simultaneously requires significant resources.
- Competitive risk: Established injectable therapies (Takhzyro, Haegarda) and emerging oral competitors (Orladeyo) exist in the HAE market.
- Dilution risk: Potential need for additional capital to fund commercial launches and ongoing trials.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-384339 |
| Document: 6-k_september_8_2026.htm | 0001193125-26-384339 |
| Document: 0001193125-26-384339-index-headers.html | 0001193125-26-384339 |
| Document: 0001193125-26-384339-index.html | 0001193125-26-384339 |
| Document: 0001193125-26-384339.txt | 0001193125-26-384339 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $38.06 $36.37 | ▲ +4.44% | ▲ +5.26% | $31.07 (+18.38%) |
Sep 14, 2026 17d ago | 144 | $38.06 $35.20 | ▼ −7.51% | ▼ −9.63% | $31.07 (−18.38%) |
Sep 14, 2026 18d ago | Insider Cluster | $38.86 $36.02 | ▼ −7.31% | ▼ −7.41% | $31.07 (−20.06%) |
Sep 11, 2026 21d ago | Insider Cluster | $38.02 $36.37 | ▼ −4.34% | ▼ −4.12% | $31.07 (−18.29%) |
Sep 8, 2026 24d ago | 6-K | $37.84 $38.86 | ▲ +2.70% | ▲ +3.36% | $31.07 (−17.90%) |
Aug 12, 2026 7w ago | 6-K | $36.46 $36.27 | ▼ −0.52% | ▼ −0.08% | $31.07 (−14.80%) |
Aug 12, 2026 7w ago | Press Release | $36.46 $36.27 | ▼ −0.52% | ▼ −0.08% | $31.07 (−14.80%) |
Aug 6, 2026 8w ago | Press Release | $34.45 $34.04 | ▼ −1.19% | ▼ −2.40% | $31.07 (−9.83%) |
Jul 6, 2026 12w ago | Press Release | $33.22 $35.07 | ▲ +5.57% | ▲ +5.08% | $31.07 (−6.49%) |
Jul 1, 2026 13w ago | Insider Cluster | $33.86 $35.96 | ▲ +6.20% | ▲ +5.27% | $31.07 (−8.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access